- Conditions
- Advanced Renal Cell Carcinoma
- Interventions
- CMN-001, Nivolumab+Ipilimumab, Lenvatinib+Everolimus
- Biological · Drug
- Lead sponsor
- CoImmune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Atlanta, Georgia • Rochester, Minnesota + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Delayed Onset Muscle Soreness
- Interventions
- SST-0225, Placebo
- Drug
- Lead sponsor
- Strategic Science & Technologies, LLC
- Industry
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- South Miami, Florida • Springfield, Missouri
- Conditions
- Glioblastoma
- Interventions
- Radiation Therapy, Personalized NeoAntigen Peptides, Pembrolizumab, Temozolomide, Poly-ICLC
- Radiation · Biological · Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
- Biological · Other · Dietary Supplement
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 30 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 7
- States / cities
- San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more
- Conditions
- Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome
- Interventions
- Buprenorphine
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- Up to 4 Weeks
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- Immune Globulin Infusion (Human), 10%, Recombinant human hyaluronidase
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 10
- States / cities
- Irvine, California • Thornton, Colorado • North Palm Beach, Florida + 7 more
- Conditions
- Solid Tumor
- Interventions
- Atezolizumab, GDC-0919
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Aurora, Colorado + 6 more
- Conditions
- COVID-19, Corona Virus Infection, Wuhan Coronavirus, Prophylaxis, Healthcare Worker, Sars-CoV2, Hydroxychloroquine
- Interventions
- Hydroxychloroquine, Placebo
- Drug
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Lafayette, Louisiana
- Conditions
- Dercum's Disease
- Interventions
- CBL-514 injection, 0.9% Sodium chloride
- Drug
- Lead sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Spokane, Washington
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- Alvimopan, Placebo
- Drug
- Lead sponsor
- Jamie N. Bakkum-Gamez
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hypersensitivity, Immediate Hypersensitivity, Food Hypersensitivity
- Interventions
- Egg oral immunotherapy, Control Group
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
- Conditions
- Immune Thrombocytopenic Purpura
- Interventions
- Rituxan, Cyclophosphamide, Vincristine, Prednisone, Higher Dose of Rituximab
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Brain Cancer, HGG, Glioma, High Grade Glioma, High Grade Gliomas, High Grade Glioma (III or IV), High Grade Glioma (HGG) of the Brain With BRAF Aberration
- Interventions
- Nivolumab, Nivolumab-IRDye800
- Drug
- Lead sponsor
- Eben Rosenthal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Metabolic Side Effects of Drugs
- Interventions
- SULT Allosteric Inhibition
- Drug
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 61 Years to 61 Years · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
- Interventions
- IV Ganciclovir, Placebo
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 14
- States / cities
- Denver, Colorado • Chicago, Illinois • Springfield, Massachusetts + 10 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Faricimab
- Drug
- Lead sponsor
- McMaster University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 11
- States / cities
- Modesto, California • Sacramento, California • Oak Forest, Illinois + 7 more
- Conditions
- Stroke
- Interventions
- Moderate-Intensity Aerobic Training, High-Intensity Interval Training
- Behavioral
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Newark, Delaware • Kansas City, Kansas • Cincinnati, Ohio
- Conditions
- Rheumatoid Arthritis
- Interventions
- Olokizumab, Placebo
- Drug
- Lead sponsor
- R-Pharm International, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor
- Interventions
- PHST001, Chemotherapy per Standard of Care
- Biological · Drug
- Lead sponsor
- Pheast Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC)
- Interventions
- Mirikizumab
- Biological
- Lead sponsor
- Rubix LS
- Industry
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lawrence, Massachusetts
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Ceralasertib, Olaparib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Plasma Cell Neoplasm
- Interventions
- Siltuximab
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Dallas, Texas • Houston, Texas
- Conditions
- Severe Hemophilia B
- Interventions
- Factor IX (rFIXFc), rFIX
- Drug
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 6 more
- Conditions
- Degenerative Arthritis
- Interventions
- Placebo, Ibuprofen modified release tablet 800 mg
- Drug
- Lead sponsor
- Overseas Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 7
- States / cities
- Cerritos, California • Garden Grove, California • Santa Ana, California + 4 more